Taevas
SingaporePharmaceuticals
Product Registration
Product Registration for Pharmaceuticals in Singapore
Taevas Global guides pharmaceutical manufacturers through Singapore's HSA product registration process, combining deep regulatory expertise with market intelligence to accelerate your compliant market entry. From dossier preparation to post-approval strat
Market
Singapore
Industry
Pharmaceuticals
Service
Product Registration
Regulator
Health Sciences Authority (HSA)
Timeline
270 days (standard); 60 days (expedited track)
What We Deliver
Six Pillars of Singapore Pharmaceuticals Intelligence
Our six interconnected pillars give pharmaceutical companies the regulatory clarity, market insight, and strategic direction needed to register products and compete confidently in Singapore.
01
Regulatory Pathway Analysis
We map the precise HSA registration route for your product, whether full evaluation, abridged, or verification pathway, so you invest effort in exactly the right dossier from day one. Our team benchmarks your product against the ASEAN Common Technical Dossier requirements and identifies any Singapore-specific deviations early. This prevents costly late-stage rework and keeps timelines predictable.
HSA pathway selection: full, abridged, or verification
ACTD and CTD gap analysis against your existing dossier
Singapore-specific labelling and product information requirements
How It Works
From Brief to Board-Ready Intelligence
Our structured four-step engagement takes you from initial product brief through to a submission-ready dossier and market entry strategy, with clear milestones and transparent communication at every stage.
Step 1 · Day 1-2
Intake and Pathway Scoping
We begin with a structured intake session to understand your product profile, existing dossier status, target indication, and commercialisation timeline. Using this information, our regulatory experts identify the applicable HSA registration pathway and produce a scoping report outlining key requirements, risks, and resource needs. This ensures all parties are aligned before any dossier work begins.
Taevas Approach
The intake session covers product classification under the Medicines Act, existing reference agency approvals that may qualify for the abridged or verification pathway, GMP certification status of your manufacturing sites, and any Singapore-specific formulation or labelling considerations. Output is a written Pathway Scoping Report delivered within two business days.
Market Snapshot
Singapore Pharmaceuticals Market at a Glance
S$0B+
Pharmaceutical Market Value
0%
Projected Annual Growth Rate
0+
Licensed Pharmaceutical Products
0+
Active Pharmaceutical Manufacturers
Regional Hub Status
Singapore serves as the regional headquarters for more than 60 multinational pharmaceutical companies, including many of the world's top 20 by revenue. The country's transparent regulatory environment, strong intellectual property protections, and skilled bilingual workforce make it the preferred base for ASEAN commercial and regulatory operations. An HSA product registration is widely regarded as a quality signal that supports subsequent filings across Southeast Asia.
HSA's Rigorous but Efficient Framework
The Health Sciences Authority operates one of Asia's most respected pharmaceutical regulatory frameworks, with evaluation timelines that compare favourably to many Western regulators when submissions are well-prepared. HSA's abridged and verification pathways allow manufacturers with prior approvals from reference agencies such as the US FDA, EMA, TGA, or Health Canada to leverage existing data for faster Singapore registration. Companies that invest in dossier quality upfront consistently achieve shorter overall approval timelines.
Growing Biologics and Specialty Segment
Singapore's pharmaceutical market is shifting toward biologics, biosimilars, and specialty medicines, driven by an ageing population and rising prevalence of chronic conditions including diabetes, cardiovascular disease, and cancer. The government's Healthier SG initiative and ongoing hospital restructuring are increasing demand for innovative therapies and creating new formulary access opportunities. Manufacturers entering with differentiated specialty products are well-positioned to capture premium pricing and long-term formulary positions.
Biomedical Manufacturing Strength
Singapore is home to a world-class pharmaceutical manufacturing cluster in Tuas and Jurong, hosting global facilities for companies including Pfizer, Sanofi, GlaxoSmithKline, and Novartis. The Economic Development Board actively supports pharmaceutical manufacturing investment through grants, infrastructure, and talent development programmes. This manufacturing ecosystem, combined with Singapore's role as a logistics hub, makes it an attractive location for both market entry and regional supply chain anchoring.
What's Included
Everything in Your Report
Every Product Registration engagement with Taevas Global delivers a comprehensive set of outputs covering regulatory strategy, dossier documentation, market intelligence, and post-approval planning.
Regulatory Pathway Report
A written assessment of the applicable HSA registration pathway for your specific product, including eligibility criteria, reference agency requirements, and a timeline projection with key milestones.
Complete CTD or ACTD Dossier Package
A fully compiled, reviewed, and HSA-formatted submission dossier covering all required modules, with an internal quality review sign-off memo confirming compliance with current HSA guidance.
Dossier Gap Analysis Report
A structured gap analysis document mapping your existing technical data against HSA requirements, with prioritised recommendations for resolving deficiencies before submission.
Regulatory Risk and Compliance Framework
A post-approval compliance roadmap covering pharmacovigilance obligations, PSUR schedules, variation classification guidance, and HSA renewal timelines specific to your registered product.
Singapore Market Entry Intelligence Brief
A concise market briefing covering competitor product landscape, pricing benchmarks, hospital and private channel dynamics, and key stakeholder mapping to support your commercial launch planning.
Local Regulatory Affairs Coordination Plan
A structured plan for establishing and maintaining your Singapore local product licence holder relationship, including HSA communication protocols and escalation procedures.
HSA Query Response Log and Tracker
A complete record of all HSA queries raised during evaluation, our drafted responses, submission dates, and resolution status, providing full audit trail documentation for your regulatory files.
ASEAN Regional Regulatory Roadmap
A strategic overview of how your Singapore registration can be leveraged for subsequent filings in key ASEAN markets, with dossier reuse recommendations and priority market sequencing guidance.
Who This Is For
Built for These Situations
First-Time Market Entry
Overseas Manufacturer Entering Singapore
You are a pharmaceutical manufacturer based in Europe, North America, or Asia Pacific with an approved product seeking to enter the Singapore market for the first time. You understand HSA's reputation but lack in-country regulatory expertise and a local product licence holder relationship. You need a partner who can manage the entire registration process end-to-end while keeping your internal team informed at every decision point.
Outcome
A fully registered product in Singapore within the projected timeline, with all post-market obligations clearly understood and a commercial launch plan ready to execute from day one of approval.
Next Steps
After Product Registration, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your Singapore Opportunity?
Taevas Global combines pharmaceutical regulatory expertise with Singapore market intelligence to help you register your product efficiently and launch with confidence. Speak with our team to discuss your product, timeline, and market entry goals.
End-to-end HSA registration management from pathway selection to product licence
Singapore-specific market intelligence to inform pricing and channel strategy
ASEAN-aligned dossier strategy to maximise regional registration value
Ongoing post-approval compliance support to protect your Singapore product licence